DOI:
10.1055/s-00034913
Phlebologie
LinksClose Window
References
Alexander JH, Becker RC, Bhatt DL. et al.
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Circulation 2009;
119: 2877-2885.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.